Chronic Sialorrhea in Adults

XEOMIN Patients Had Significant and Sustained Reductions in Unstimulated Salivary Flow Rate (uSFR)1,2

Image of chart showing the improvements in unstimulated salivary flow rate (uSFR) were sustained over 16 weeks.

Pivotal Trial Design

Randomized, Double-blind, Placebo-controlled
Trial of XEOMIN in Adult Patients with Chronic Sialorrhea1

Clinical trial of XEOMIN® in adult patients with chronic sialorrhea.

*XEOMIN is only approved for chronic sialorrhea in adults at the 100-Unit dose. The 75-Unit dose was not statistically better than placebo.

Reference

  1. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982-e1991.

XEOMIN Patients Had Sustained Improvements in
Global Impression of Change Scale (GICS)

Improvements in the Global Impression of Change Scale (GICS) were sustained over 16 weeks.

References

  1. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982-e1991.
  2. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.
  3. Data on file. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.